 Graft vs Host Disease
"Graft vs Host Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Descriptor ID |
D006086
|
| MeSH Number(s) |
C20.452
|
| Concept/Terms |
Graft vs Host Disease- Graft vs Host Disease
- Graft-Versus-Host Disease
- Disease, Graft-Versus-Host
- Diseases, Graft-Versus-Host
- Graft Versus Host Disease
- Graft-Versus-Host Diseases
- Runt Disease
- Disease, Runt
- Graft-vs-Host Disease
- Disease, Graft-vs-Host
- Diseases, Graft-vs-Host
- Graft-vs-Host Diseases
- Homologous Wasting Disease
- Disease, Homologous Wasting
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Host Disease".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Host Disease".
This graph shows the total number of publications written about "Graft vs Host Disease" by people in this website by year, and whether "Graft vs Host Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1993 | 2 | 0 | 2 | | 1994 | 2 | 0 | 2 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 2 | 3 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 3 | 2 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 1 | 2 | | 2004 | 3 | 1 | 4 | | 2005 | 2 | 4 | 6 | | 2006 | 2 | 3 | 5 | | 2007 | 4 | 5 | 9 | | 2008 | 3 | 2 | 5 | | 2009 | 4 | 6 | 10 | | 2010 | 3 | 4 | 7 | | 2011 | 5 | 4 | 9 | | 2012 | 5 | 5 | 10 | | 2013 | 7 | 0 | 7 | | 2014 | 7 | 7 | 14 | | 2015 | 8 | 5 | 13 | | 2016 | 12 | 9 | 21 | | 2017 | 7 | 3 | 10 | | 2018 | 8 | 4 | 12 | | 2019 | 6 | 4 | 10 | | 2020 | 4 | 0 | 4 | | 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Graft vs Host Disease" by people in Profiles.
-
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. 2021 06 01; 106(6):1599-1607.
-
Thangavelu G, Wang C, Loschi M, Saha A, Osborn MJ, Furlan SN, Aoyama K, McDonald-Hyman C, Aguilar EG, Janesick AS, Chandraratna RA, Refaeli Y, Panoskaltsis-Mortari A, MacDonald KP, Hill GR, Zeiser R, Maillard I, Serody JS, Murphy WJ, Munn DH, Blumberg B, Brown C, Kuchroo V, Kean LS, Hippen KL, Noelle RJ, Blazar BR. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood. 2021 02 25; 137(8):1090-1103.
-
Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, Solh MM, Bashey A. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020 10 27; 4(20):5311-5321.
-
Milano F, Gutman JA, Deeg HJ, Nemecek ER, Baumgart J, Thur L, Dahlberg A, Salit RB, Summers C, Appelbaum FR, Delaney C. Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. Blood Adv. 2020 07 28; 4(14):3302-3310.
-
Koo J, Giller RH, Quinones R, McKinney CM, Verneris MR, Knight-Perry J. Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects. Pediatr Blood Cancer. 2020 09; 67(9):e28591.
-
Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 05 26; 4(10):2227-2235.
-
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG. Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):606-611.
-
Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight. 2019 10 03; 4(19).
-
Niehrs A, Garcia-Beltran WF, Norman PJ, Watson GM, Hölzemer A, Chapel A, Richert L, Pommerening-Röser A, Körner C, Ozawa M, Martrus G, Rossjohn J, Lee JH, Berry R, Carrington M, Altfeld M. A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. Nat Immunol. 2019 09; 20(9):1129-1137.
-
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019 Aug; 6(8):e409-e418.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|